Duke logo

STARTRK-2 for Advanced Solid Tumors with NTRK1/2/3, ROS1, or ALK Gene Rearrangements - Clinical Trial

What is the Purpose of this Study?

We are doing this study to learn if the study drug (entrectinib) is safe and will work in patients with advanced cancer with a gene mutation.

What is the Condition Being Studied?

Solid tumor cancer with specific gene mutations

Who Can Participate in the Study?

Adults diagnosed with solid tumor cancer that has a gene mutation (NTRK1/2/3, ROS1, or ALK gene rearrangement).

Age Group
Adults

What is Involved?

If you choose to be in this study you will:
- Have blood drawn, and a possible tumor tissue biopsy
- Physical and eye exam
- Complete quality of life surveys
- Take study drug (entrectinib) by mouth every day
- Take part in this study until your disease worsens or your study doctor requests you to stop

Study Details

Full Title
An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements
Principal Investigator
Medical Oncologist
Protocol Number
IRB:PRO00078723
NCT:NCT02568267
Phase
Phase II
ClinicalTrials.gov
Contact the Duke Recruitment Innovation Center
studyrecruitment@duke.edu
or
919-681-5698